STEMMEDICAL® has done ground-breaking work in stem cells, as published in The Lancet in 2013. Building on this work, StemMedical is the first and only company in the world to commercially offer stem cell products targeting the €40 billion cosmetic surgery market with more than 10 million procedures annually.
In addition, the StemMedical cell platform is versatile and can further address regenerative treatment of major unmet needs, e.g., musculoskeletal disorders like osteoarthritis with more than 500 million patients.
StemMedical® has done ground-breaking work in mesenchymal stem cells, which has opened a pipeline of treatment opportunities. StemMedical® is now first in the world to commercially offer stem cell-based products for aesthetic and reconstructive surgery after a decade of R&D and clinical treatments.